1. Cancers (Basel). 2022 Jun 18;14(12):3012. doi: 10.3390/cancers14123012.

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: 
Results of the GIMEMA AML1516 Protocol.

Messina M(1), Piciocchi A(1), Ottone T(2)(3), Paolini S(4), Papayannidis C(4), 
Lessi F(5), Fracchiolla NS(6), Forghieri F(7), Candoni A(8), Mengarelli A(9), 
Martelli MP(10), Venditti A(2), Carella AM(11), Albano F(12), Mancini V(13), 
Massimo B(14), Arena V(1), Sargentini V(1), Sciumè M(6), Pastore D(15), Todisco 
E(16), Roti G(17), Siragusa S(18), Ladetto M(19), Pravato S(5), De Bellis E(20), 
Simonetti G(21), Marconi G(22), Cerchione C(22), Fazi P(1), Vignetti M(1), 
Amadori S(2), Martinelli G(21), Voso MT(2)(3).

Author information:
(1)GIMEMA Foundation, 00182 Roma, Italy.
(2)Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma Tor 
Vergata, 00133 Roma, Italy.
(3)Neuro-Oncohematology Unit, IRCCS Fondazione Santa Lucia, 00179 Roma, Italy.
(4)IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 
"Seràgnoli" Bologna, 40138 Bologna, Italy.
(5)Ematologia ed Immunologia Clinica, Università degli Studi di Padova, 1222 
Padua, Italy.
(6)UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
20122 Milano, Italy.
(7)UO Ematologia-AOU Policlinico di Modena, 41125 Modena, Italy.
(8)Clinica Ematologica, ASUFC, Università degli Studi di Udine, 33100 Udine, 
Italy.
(9)UO Ematologia-IRCCS Istituto Nazionale Tumori Tumori Regina Elena, 00128 
Roma, Italy.
(10)Sezione di Ematologia ed Immunologia Clinica, Università degli Studi di 
Perugia, 06123 Perugia, Italy.
(11)Ematologia e Centro Trapianti CSE Fondazione IRCCS Casa Sollievo della 
Sofferenza, 71013 San Giovanni Rotondo, Italy.
(12)Hematology and Stem Cell Transplantation Unit, Department of Emergency and 
Organ Transplantation (D.E.T.O.), University of Bari Aldo Moro, 70121 Bari, 
Italy.
(13)Ospedale Niguarda Ca Granda-SC Ematologia Blocco SUD, 20162 Milano, Italy.
(14)IRCCS San Raffaele Scientific Institute, 20132 Milano, Italy.
(15)UOC Ematologia Brindisi, 72100 Brindisi, Italy.
(16)Onco-Hematology Division, IEO European Institute of Oncology IRCCS, 20141 
Milan, Italy.
(17)Azienda Ospedaliera Universitaria di Parma, Ematologia, Università di Parma, 
43126 Parma, Italy.
(18)U.O. di Ematologia con Trapianto-A.U. Policlinico Paolo Giaccone, 90127 
Palermo, Italy.
(19)AO SS Antonio e Biagio Arrigo, 15121 Alessandria, Italy.
(20)Hematology Unit, Azienda Sanitaria Universitaria Giuliano Isontina, 34148 
Trieste, Italy.
(21)Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori 
(IRST) Dino Amadori, 47014 Meldola, Italy.
(22)Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei 
Tumori [M1] (IRST) IRCCS, 47014 Meldola, Italy.

IDH1/2 mutations are common in acute myeloid leukemia (AML) and represent a 
therapeutic target. The GIMEMA AML1516 observational protocol was designed to 
study the prevalence of IDH1/2 mutations and associations with 
clinico-biological parameters in a cohort of Italian AML patients. We analyzed a 
cohort of 284 AML consecutive patients at diagnosis, 139 females and 145 males, 
of a median age of 65 years (range: 19−86). Of these, 38 (14%) harbored IDH1 and 
51 (18%) IDH2 mutations. IDH1/2 mutations were significantly associated with WHO 
PS >2 (p < 0.001) and non-complex karyotype (p = 0.021) when compared to 
IDH1/2-WT. Furthermore, patients with IDH1 mutations were more frequently 
NPM1-mutated (p = 0.007) and had a higher platelet count (p = 0.036). At 
relapse, IDH1/2 mutations were detected in 6 (25%) patients. As per the outcome, 
60.5% of IDH1/2-mutated patients achieved complete remission; overall survival 
and event-free survival at 2 years were 44.5% and 36.1%, respectively: these 
rates were similar to IDH1/2-WT. In IDH1/2-mutated patients, high WBC proved to 
be an independent prognostic factor for survival. In conclusion, the GIMEMA 
AML1516 confirms that IDH1/2 mutations are frequently detected at diagnosis and 
underlines the importance of recognizing IDH1/2-mutated cases up-front to offer 
the most appropriate therapeutic strategy, given the availability of IDH1/2 
inhibitors.

DOI: 10.3390/cancers14123012
PMCID: PMC9221405
PMID: 35740677

Conflict of interest statement: M.V.: Amgen; Novartis, Mattioli srl; IQVIA; 
Dephaforum S.r.l.; M.L.: AbbVie, Acerta, Amgen, ADC Therapeutics, Astra Zeneca, 
BeiGene Celgene, GSKI, Gentili, Gilead/Kite, Novartis, Incyte J and J, Jazz, 
Regeneron, Roche, Sandoz, Takeda. Non-financial interests: PI or strategic 
investigator in studies supported by: Celgene, J&J, BeiGene, ADC Therapeutics; 
GMartinelli: Abbvie; Incyte; Pfizer; Celgene/BMS; Amgen, Roche; GlaxoSmithKline; 
Astellas; Daiichi Sankyo; Takeda; Janssen; Servier. Research support from: 
Pfizer, AbbVie, AstraZeneca, Daiichi Sankyo, Takeda, and Ariad/Incyte. GMarconi: 
Menarini/stemline, Pfizer, Servier, and Astellas and research support from 
Pfizer, AbbVie, and AstraZeneca. The other authors declare no conflict of 
interest. The funders had no role in the design of the study; in the collection, 
analyses, or interpretation of data; in the writing of the manuscript, or in the 
decision to publish the results.